Keros Therapeutics vs Proqr Therapeutics
Keros Therapeutics is the larger business, with $244m of revenue in fiscal 2025 against $18.0m for Proqr Therapeutics (13.6 times as much). Keros Therapeutics grew faster (6769.4% against -12.1%). Keros Therapeutics kept more of each dollar of sales as profit: a net margin of 35.7% against -265.2%. Keros Therapeutics carries less debt relative to equity (0.0% against 9.9%).
| Latest fiscal year | Keros TherapeuticsKROS, 2025 | Proqr TherapeuticsPRQR, 2025 |
|---|---|---|
| Revenue | $244m | $18.0m |
| Revenue growth | 6769.4% | -12.1% |
| Net income | $87.0m | −$47.7m |
| Operating margin | 27.7% | -273.1% |
| Net margin | 35.7% | -265.2% |
| Return on equity | 19.9% | -63.8% |
| Free cash flow | $106m | −$60.8m |
| Cash | $287m | $108m |
| Total debt | $0 | $5.7m |
| Debt to equity | 0.0% | 9.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $375m | — |
| Employees | 78 | — |
| Market value | $215m | $144m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 6 buys, 12 sales | 5 buys, 0 sales |